LDLR-fucosyltransferaseAS fusion protein (315-323)

LDLR-fucosyltransferaseAS fusion protein (315-323) is a synthetic peptide construct representing a specific segment of a fusion protein composed of the low-density lipoprotein receptor (LDLR) and fucosyltransferase AS. As a defined peptide fragment, it encompasses residues 315 to 323 of the fusion protein, providing a valuable biochemical tool for dissecting the structural and functional properties of LDLR-fucosyltransferase interactions. The sequence is designed for use in advanced molecular studies, enabling researchers to investigate the interface between receptor-mediated endocytosis and glycosylation processes. By isolating this region, the peptide offers insights into the role of specific amino acids in modulating protein-protein interactions and post-translational modifications relevant to lipid metabolism and glycan biosynthesis.

Epitope mapping: The defined sequence of the LDLR-fucosyltransferaseAS fusion protein (315-323) peptide makes it a powerful tool for epitope mapping studies. Researchers can utilize this fragment to identify antibody binding sites, helping to characterize immune recognition patterns within the fusion protein. Such investigations are crucial for the development of diagnostic reagents, as well as for understanding the immunogenicity of engineered protein constructs in basic and applied research contexts.

Protein-protein interaction analysis: The peptide serves as a model substrate for investigating the molecular determinants of LDLR and fucosyltransferase AS association. By employing this fragment in binding assays, surface plasmon resonance, or co-immunoprecipitation experiments, scientists can dissect the specific contributions of the 315-323 region to the overall interaction interface. This targeted approach enables the elucidation of key residues involved in complex formation, advancing knowledge of receptor-glycosyltransferase crosstalk.

Peptide-based inhibitor screening: The LDLR-fucosyltransferaseAS fusion protein (315-323) fragment can be used in high-throughput screening assays to identify small molecules or peptides that disrupt or modulate the interaction between LDLR and fucosyltransferase domains. By serving as a competitive binding substrate, it facilitates the discovery of novel modulators that may be relevant for controlling glycosylation pathways or receptor-mediated signaling in cellular models.

Structural and conformational studies: The well-defined nature of the peptide allows for detailed structural analyses using techniques such as circular dichroism spectroscopy, NMR, or X-ray crystallography (in complex with binding partners). These studies provide insight into the secondary structure, conformational flexibility, and potential structural motifs present within the 315-323 region. Understanding these features is essential for rational protein engineering and for predicting the impact of sequence variations on function.

Immunoassay development: The peptide fragment is suitable for use as a standard or calibrator in immunoassays designed to detect or quantify antibodies against the LDLR-fucosyltransferase fusion protein. Its precise sequence and synthetic reproducibility make it an ideal choice for assay validation, specificity testing, and the establishment of quantitative benchmarks in research settings. Utilizing this peptide in immunoassays supports the development of reliable analytical tools for protein detection and characterization.

1. High fat diet and GLP-1 drugs induce pancreatic injury in mice

2. Investigating Potential Interactions Between Neurohypophyseal Peptides, their Drug Analogs, and Coagulation Factor VIII

3. Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction

4. TMEM16F and dynamins control expansive plasma membrane reservoirs

5. Cationic cell-penetrating peptides are potent furin inhibitors